参考文献/References:
[1] Okazaki T, Chikuma S, Iwai Y, et al.A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application [J].Nat Immunol,2013, 14(12): 1212-1218.
[2] Robert C, Schachter J, Long G V, et al.Pembrolizumab versus ipilimumab in advanced melanoma [J].N Engl J Med, 2015, 372(26): 2521-2532.
[3] Reck M, Rodríguez-Abreu D, Robinson A G, et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [J].N Engl J Med, 2016, 375(19): 1823-1833.
[4] Escudier B, Motzer R J, Tannir N M, et al.Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in checkmate 214 [J/OL].Eur Urol,(2019-11-13)[2020-02-20].http://www.ncbi.nlm.nih.gov/pmc/. DOI:10.1016/j.eururo.2019.10.025
[5] Wang L, Kang F B, Shan B E, et al.B7-H3-mediated tumor immunology: Friend or foe?[J].Int J Cancer, 2014,134(12): 2764-2771.
[6] Inamura K, Yokouchi Y, Kobayashi M, et al.Tumor B7-H3(CD276)expression and smoking history in relation to lung adenocarcinoma prognosis [J].Lung Cancer, 2017, 103:44-51.
[7] Yonesaka K, Haratani K, Takamura S, et al.B7-H3 nega-tively modulates CTL-mediated cancer immunity [J].Clin Cancer Res, 2018, 24(11): 2653-2664.
[8] Crispen P L, Sheinin Y, Roth T J, et al.Tumor cell and tumor vasculature expression of b7-h3 predict survival in clear cell renal cell carcinoma [J].Clin Cancer Res, 2008, 14(16): 5150-5157.
[9] Thompson R H, Kuntz S M, Leibovich B C, et al.Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up [J].Cancer Res, 2006, 66(7): 3381-3385.
[10] Thompson R H, Gillett M D, Cheville J C, et al.Costimula-tory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma [J].Cancer, 2005, 104(10):2084-2091.
[11] Ribas A.Tumor immunotherapy directed at PD-1 [J].N Engl J Med, 2012, 366(26): 2517-2519.
[12] Choueiri T K, Figueroa D J, Fay A P,et al.Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from comparz, a randomized controlled trial [J].Clin Cancer Res, 2015, 21(5):1071-1077.
[13] Mischinger J, Fr?hlich E, Mannweiler S, et al.Prognostic value of B7-H1, B7-H3 and the SSIGN score in metastatic clear cell renal cell carcinoma [J].Cent European J Urol, 2019, 72(1): 23-31.
[14] Castellanos J R, Purvis I J, Labak C M, et al.B7-H3 role in the immune landscape of cancer [J].Am J Clin Exp Immunol, 2017, 6(4): 66-75.
[15] Patel S P, Kurzrock R.PD-L1 Expression as a predictive biomarker in cancer immunotherapy [J].Mol Cancer Ther, 2015, 14(4): 847-856.
[16] Brahmer J, Reckamp K L, Baas P, et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [J].N Engl J Med,2015, 373(2):123-135.